# Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®

> **NCT02722122** · PHASE2 · UNKNOWN · sponsor: **Protalix** · enrollment: 15 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** AIR DNase™

## Key facts

- **NCT ID:** NCT02722122
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2017-02
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722122, "Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02722122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*